Hepatocellular Carcinoma Market is expected to reach USD 2.4 billion by 2031 and grow with a CAGR of 12.2% | Bristol Myers Squibb, Novartis AG, Bayer AG.

The Global Hepatocellular Carcinoma Market reached USD 977 million in 2022 and is expected to reach USD 2.4 billion by 2031 and grow with a CAGR of 12.2% during the forecast period 2024-2031.

Hepatocellular Carcinoma Market report, published by DataM Intelligence, provides in-depth insights and analysis on key market trends, growth opportunities, and emerging challenges. Committed to delivering actionable intelligence, DataM Intelligence empowers businesses to make informed decisions and stay ahead of the competition. Through a combination of qualitative and quantitative research methods, it offers comprehensive reports that help clients navigate complex market landscapes, drive strategic growth, and seize new opportunities in an ever-evolving global market.

Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):- https://datamintelligence.com/download-sample/hepatocellular-carcinoma-market?rk

Hepatocellular carcinoma (HCC) is the most common type of primary liver cancer, often associated with chronic liver diseases like hepatitis B, hepatitis C, and cirrhosis. It is a highly aggressive cancer with limited treatment options, including surgery, liver transplantation, targeted therapy, and immunotherapy. Early detection through imaging and biomarkers is crucial for improving survival rates. Advances in precision medicine are revolutionizing HCC treatment by offering more effective, personalized approaches. Growing research in oncology and liver disease management is fueling market expansion.

List of the Key Players in the Hepatocellular Carcinoma Market:

Teva Pharmaceutical Industries Ltd., Bristol Myers Squibb, Novartis AG, Bayer AG, F. Hoffmann-La Roche Ltd, Polaris Pharmaceuticals Inc., Creative Diagnostics, Harbour BioMed and Merck & Co. Inc. among others.

Industry Development:

On May 26, 2023, at the Annual Meeting of the American Society of Clinical Oncology (ASCO) 2023, Harbour BioMed, a biopharmaceutical company focused on developing and commercializing novel antibody treatments, presented the findings of a phase Ib clinical study on porustobart (HBM4003) in combination with toripalimab for patients with hepatocellular carcinoma (HCC).

Market Dynamics:

The rising efforts for early and rapid detection of hepatocellular carcinoma (HCC) in the healthcare industry are expected to drive market growth over the forecast period. The American Association for the Study of Liver Diseases recommends HCC screening for at-risk individuals, including those with cirrhosis, as studies have highlighted a strong correlation between screening and improved early detection, curative treatment, and reduced HCC-related mortality. However, HCC remains challenging to detect due to its complex pathophysiology and diverse genetic, environmental, and viral causes. Currently, abdominal ultrasonography, with or without AFP biomarker screening, is the primary diagnostic method for high-risk patients. Translational advancements in biomarkers, next-generation sequencing (NGS), molecular imaging, artificial intelligence, and liquid biopsy hold promise for earlier and more accurate HCC diagnosis.

Growth Forecast Projected:

The Global Hepatocellular Carcinoma Market is anticipated to rise at a considerable rate during the forecast period, between 2024 and 2031. In 2023, the market is growing at a steady rate, and with the rising adoption of strategies by key players, the market is expected to rise over the projected horizon.

Research Process:

Both primary and secondary data sources have been used in the global Hepatocellular Carcinoma Market research report. During the research process, a wide range of industry-affecting factors are examined, including governmental regulations, market conditions, competitive levels, historical data, market situation, technological advancements, upcoming developments, in related businesses, as well as market volatility, prospects, potential barriers, and challenges.

Make an Enquiry for purchasing this Report @ https://www.datamintelligence.com/enquiry/hepatocellular-carcinoma-market?rk

Segment Covered in the Hepatocellular Carcinoma Market:

By Treatment: Chemotherapy, Brachytherapy, Local Ablation Therapy, Surgery, Others.

By End-User: Hospitals, Cancer rehabilitation centers, Clinics, Others.

Regional Analysis for Hepatocellular Carcinoma Market:

The regional analysis of the Hepatocellular Carcinoma Market covers key regions including North America, Europe, Asia Pacific Middle East and Africa and South America. The North America with a focus on the U.S., Canada, and Mexico; Europe, highlighting major countries like the U.K., Germany, France, and Italy, along with other nations in the region; Asia-Pacific, covering India, China, Japan, South Korea, and Australia, among others; South America, with emphasis on Colombia, Brazil, and Argentina; and the Middle East & Africa, which includes Saudi Arabia, the U.A.E., South Africa, and other countries. This comprehensive regional breakdown helps identify unique market trends and growth opportunities specific to each area.

⇥ North America (U.S., Canada, Mexico)

⇥ Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)

⇥ Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)

⇥ South America (Colombia, Brazil, Argentina, Rest of South America)

⇥ Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

Benefits of the Report:

➡ A descriptive analysis of demand-supply gap, market size estimation, SWOT analysis, PESTEL Analysis and forecast in the global market.

➡ Top-down and bottom-up approach for regional analysis

➡ Porter's five forces model gives an in-depth analysis of buyers and suppliers, threats of new entrants & substitutes and competition amongst the key market players.

➡ By understanding the value chain analysis, the stakeholders can get a clear and detailed picture of this Market

Speak to Our Analyst and Get Customization in the report as per your requirements: https://datamintelligence.com/customize/hepatocellular-carcinoma-market?rk

People Also Ask:

➠ What is the global sales, production, consumption, import, and export value of the Hepatocellular Carcinoma market?

➠ Who are the leading manufacturers in the global Hepatocellular Carcinoma industry? What is their operational status in terms of capacity, production, sales, pricing, costs, gross margin, and revenue?

➠ What opportunities and challenges do vendors in the global Hepatocellular Carcinoma industry face?

➠ Which applications, end-users, or product types are expected to see growth? What is the market share for each type and application?

➠ What are the key factors and limitations affecting the growth of the Hepatocellular Carcinoma market?

➠ What are the various sales, marketing, and distribution channels in the global industry?

Browse More Reports: https://www.datamintelligence.com/research-report/hepatocellular-carcinoma-market?rk

Pancreatic Cancer Market: https://datamintelligence.com/research-report/pancreatic-cancer-market?rk

Non Melanoma Skin Cancer Market: https://datamintelligence.com/research-report/non-melanoma-skin-cancer-market?rk

Contact Us -

Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -

DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.